Site is Being Upgraded

Molecular therapy for pulmonary arterial hypertension: Omeprazole (Brand name: Prilosec, Losec), a drug used to treat stomach and intestinal ulcers, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 26/January/2018, 11.11 pm

Natural product-derived therapy for anxiety and depression: Triptolide, isolated from Thunder God Vine, decreases PHF8 levels, increases the expression of serotonin receptors Htr1a and Htr2a, and promotes resistance to stress-induced -anxiety and -depression via down regulation of its target gene, 26/January/2018, 11.02 pm
January 26, 2018
Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Pantoprazole  and Pyridoxamine (PAP) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 26/January/2017, 11.22 pm
January 26, 2018
Show all

What they say: 

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054],  by Prof. Thistlethwaite PA, Li X and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Molecular therapy for pulmonary arterial hypertension: Lansoprazole (Brand name: Prevacid), a drug used to treat stomach and intestinal ulcers, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3


Significance of the study:  

Omeprazole has been shown to shown to lower stomach acid. However, its mechanism of action is far from understood. 

This study suggests, for the first time, that Omeprazoleby increasing the expression of its target gene, it may decrease, in dose-dependent manner, the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1).  Thus, pharmacological formulations encompassing “Omeprazole or its analogues, either alone or in combination with other drugs,” may be used to treat pulmonary arterial hypertension (Figure 2).

Figure 1. Mechanistic insights into how Omeprazole inhibits the development of pulmonary hypertension through regulation of its target genes

Figure 2. The chemical structure of Omeprazole


Details of the research findings: 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Undisclosed mechanistic information: How Omeprazole  decreases the expression of Notch3 and its target gene

Amount: $500#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L.,  Molecular therapy for pulmonary arterial hypertension: Omeprazole (Brand name: Prilosec, Losec), a drug used to treat stomach and intestinal ulcers, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 26/January/2018, 11.11 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.